<DOC>
	<DOCNO>NCT02522234</DOCNO>
	<brief_summary>This study phase Ib study safety pharmacokinetics/pharmacodynamics F-627 per cycle prophylaxis therapy chemotherapy woman breast cancer . The patient receive intravenous administration chemotherapy ( docetaxol , doxorubicin cyclophosphamide , 75 mg/m2 , 50 mg/m2 500 mg/m2 respectively ) Day 1 subcutaneous injection F-627 240 µg/kg 320 µg/kg Day 2 ( approximately 24 hour chemotherapy ) cycle 6 cycle .</brief_summary>
	<brief_title>A Pharmacokinetics/Dynamics Ib Study F-627 Women With Breast Cancer Receiving Myelotoxic Chemotherapy</brief_title>
	<detailed_description>This study phase Ib study safety pharmacokinetics/pharmacodynamics F-627 per cycle prophylaxis therapy chemotherapy woman breast cancer . This study conduct two center China enrol 15 patient breast cancer receive TAC chemotherapy ( docetaxel , doxorubicin cyclophosphamide ) . The patient receive intravenous administration chemotherapy ( docetaxol , doxorubicin cyclophosphamide , 75 mg/m2 , 50 mg/m2 500 mg/m2 respectively ) Day 1 subcutaneous injection F-627 240 µg/kg 320 µg/kg Day 2 ( approximately 24 hour chemotherapy ) cycle 6 cycle . Patients remain study drug dose follow 6 chemotherapy cycle . Patients remain study drug dose follow 6 chemotherapy cycle . The blood sample collect F-627 serum concentration analysis cycle 1 3 .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . 1875 year old ; 2 . Female breast cancer patient resection plan receive 6 cycle chemotherapy ( docetaxol , doxorubicin cyclophosphamide ) . 3 . Score 01 East Cooperative Oncology Group ( ECOG ) . 4 . Absolute neutrophil count ( ANC ) ≥ 2.0 × 109/L , hemoglobin ( Hb ) ≥ 11.0 g/dl , platelet ( PLT ) ≥ 100 × 109/L prior chemotherapy ; 5 . Liver kidney function test within normal range ; 6 . Left ventricular ejection fraction ( LVEF ) &gt; 50 % ; 7 . Willing provide write informed consent compliant study procedure . 1 . Pregnancy lactate woman ; female pregnancy potential positive pregnancy test prior study treatment . 2 . Expected survival &lt; 12 month . 3 . Patients receive radiotherapy within 4 week prior enrollment . 4 . Patients receive neoadjuvant chemotherapy prior resection breast cancer . 5 . Patients receive bone marrow hemopoietic stem cell transplantation ; 6 . Patient malignancy breast cancer . 7 . Patients receive GCSF treatment within 6 week prior enrollment . 8 . Patient n't tolerate pretreatment chemotherapy . 9 . Acute congestive heart failure , myocardial disease , myocardial infarction diagnose clinical , electrocardiography , medical procedure . 10 . Any disease possibly cause splenomegaly . 11 . Acute infection , chronic active hepatitis B infection within 1 year ( except subject negative hepatitis B antigen prior enrollment ) history hepatitis C infection . 12 . Patients active tuberculosis ( TB ) , ever history close contact patient TB except negative result tuberculin test ; TB treatment ; suspect TB chest Xray . 13 . Known positive result human immunodeficiency virus ( HIV ) patient acquire immune deficiency syndrome ( AIDS ) . 14 . Patients sicklecell anemia . 15 . Patients alcohol abuse drug addiction may affect compliance study . 16 . Patients allergy protein extract Escherichia coli , GCSF , drug excipient . 17 . Patients take investigational product within 4 week prior enrollment . 18 . Patients diseases symptom may suitable enrol study base investigator 's judgment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>